Phase 2CompletedAge-related condition
A Study to Find the Best Dose of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause (Starlight)
A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Select the Optimal Dose(s) of Fezolinetant in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause in Japan
- Sponsor
- Astellas Pharma Inc (Industry)
- Enrollment
- 147 enrolled
- Conditions
- Hot Flashes
- Interventions
- Fezolinetant; Placebo
- Ages
- adults, older adults
- Registry
- NCT05034042, jRCT2031210334
Full record on ClinicalTrials.gov
From the registry
This study is for menopausal women who have hot flashes. Menopause, a normal part of life, is the time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life. This study will take place in Japan. This study will provide more information on a potential new treatment, called fezolinetant. The treatments in this study are fezolinetant or a placebo. In this study, a placebo is a dummy treatment that looks like fezolinetant but does not have any medicine in it. The study will compare fezolinetant with the placebo to find the best dose of fezolinetant to reduce the number and severity of hot flashes. Women that want to take part in the study will be given an electronic handheld device to track their hot flashes. In the last 10 days before their next clinic visit, the women will record information about their hot flashes. Women will be picked for 1 of 3 treatments (lower or higher dose of fezolinetant, or placebo) by chance alone. Women who take part in the study will take 2 tablets every day for 12 weeks. Treatment will be…
Primary outcomes
- Mean change from baseline in the frequency of mild, moderate and severe vasomotor symptom (VMS)
History
Last registry update
Study completion
Primary completion
Started
Registered